Cargando…

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models

Inhibition of the cyclin‐dependent kinase (CDK) 4/6‐retinoblastoma (RB) pathway is an effective therapeutic strategy against cancer. Here, we performed a preclinical investigation of the antitumor activity of SHR6390, a novel CDK4/6 inhibitor. SHR6390 exhibited potent antiproliferative activity agai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Fei, He, Ye, Fu, Haoyu, Li, Yun, Bao, Xubin, Wang, Quanren, Wang, Yigang, Xie, Chengying, Lou, Liguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447953/ https://www.ncbi.nlm.nih.gov/pubmed/30724426 http://dx.doi.org/10.1111/cas.13957

Ejemplares similares

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
por: Liu, Yan-ping, et al.
Publicado: (2022)

A mass balance study of [(14)C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
por: Zhang, Hua, et al.
Publicado: (2023)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
por: Wang, Jiayuan, et al.
Publicado: (2017)

Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin
por: Xie, Chengying, et al.
Publicado: (2017)

Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist
por: Xie, Chengying, et al.
Publicado: (2018)

SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
por: Tong, Mengya, et al.
Publicado: (2019)

Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials
por: Wang, Lei, et al.
Publicado: (2019)

Genomic analysis of the progenitor strains of Staphylococcus aureus RN6390
por: Garrett, Stephen R., et al.
Publicado: (2022)

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
por: Xie, Chengying, et al.
Publicado: (2018)

Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
por: Gao, Mingzhao, et al.
Publicado: (2019)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition
por: Sun, Liping, et al.
Publicado: (2014)

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
por: Li, Huiping, et al.
Publicado: (2020)

NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations
por: Zhao, Jie, et al.
Publicado: (2014)

Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS
por: Xiao, Mei, et al.
Publicado: (2023)

Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia
por: Xie, Chengying, et al.
Publicado: (2017)

Haem-iron plays a key role in the regulation of the Ess/type VII secretion system of Staphylococcus aureus RN6390
por: Casabona, M. Guillermina, et al.
Publicado: (2017)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
por: Laha, Dipranjan, et al.
Publicado: (2022)

X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response
por: Zhao, Zhixin, et al.
Publicado: (2016)

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
por: James, Alexander D., et al.
Publicado: (2020)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Spatial Memory in Spontaneously Hypertensive Rats (SHR)
por: Sontag, Thomas-A., et al.
Publicado: (2013)

Patient-derived xenografts as preclinical neuroblastoma models
por: Braekeveldt, Noémie, et al.
Publicado: (2017)

Cardioprotective Regimen of Adaptation to Chronic Hypoxia Diversely Alters Myocardial Gene Expression in SHR and SHR-mt(BN) Conplastic Rat Strains
por: Nedvedova, Iveta, et al.
Publicado: (2019)

Effects of RMF on BKCa and Kv channels in basilar arterial smooth-muscle cells of SHR
por: Qian, Yan-Fei, et al.
Publicado: (2017)

Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease
por: Sun, Xi, et al.
Publicado: (2021)

Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells
por: Zhang, Mi, et al.
Publicado: (2021)

Vasorelaxant and Hypotensive Effects of Cheonwangbosimdan in SD and SHR Rats
por: Kim, Bumjung, et al.
Publicado: (2018)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
por: Ma, Tingting, et al.
Publicado: (2022)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

Categorizing SHR and WKY rats by chi2 algorithm and decision tree
por: Tsai, Ping-Rui, et al.
Publicado: (2021)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

Antioxidant resveratrol restores renal sodium transport regulation in SHR
por: Javkhedkar, Apurva A, et al.
Publicado: (2015)

Quantification of platelets obtained by different centrifugation protocols in SHR rats()
por: Yazigi Junior, João Alberto, et al.
Publicado: (2015)

Insufficient hypothalamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats
por: Wang, Kun, et al.
Publicado: (2017)

MODL-05 Metronomic Intrathecal Delivery of CDK4/6 Inhibitors in Preclinical Models of Pediatric Brain Tumors
por: Guadix, Sergio, et al.
Publicado: (2022)

Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models
por: Syn, Nicholas L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_db79v66sm43cjo0e951kuuk4ro